当前位置:
X-MOL 学术
›
JAMA Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy
JAMA Oncology ( IF 22.5 ) Pub Date : 2025-01-30 , DOI: 10.1001/jamaoncol.2024.6168
Sarah E. Lochrin, Hannah L. Kalvin, James W. Smithy, Monica F. Chen, Parisa Momtaz, Alexander N. Shoushtari, Katherine S. Panageas, Michael A. Postow
JAMA Oncology ( IF 22.5 ) Pub Date : 2025-01-30 , DOI: 10.1001/jamaoncol.2024.6168
Sarah E. Lochrin, Hannah L. Kalvin, James W. Smithy, Monica F. Chen, Parisa Momtaz, Alexander N. Shoushtari, Katherine S. Panageas, Michael A. Postow
This cohort study examines the response and survival rates associated with ipilimumab-nivolumab therapy in patients with progressive melanoma brain metastases after anti–programmed cell death 1 (anti–PD-1) therapy.
中文翻译:
Ipilimumab 和 Nivolumab 在抗 PD-1 治疗进展后黑色素瘤脑转移中的颅内结果
该队列研究检查了抗程序性细胞死亡 1 (抗-PD-1) 治疗后进行性黑色素瘤脑转移患者与 ipilimumab-nivolumab 治疗相关的反应和存活率。
更新日期:2025-01-30
中文翻译:

Ipilimumab 和 Nivolumab 在抗 PD-1 治疗进展后黑色素瘤脑转移中的颅内结果
该队列研究检查了抗程序性细胞死亡 1 (抗-PD-1) 治疗后进行性黑色素瘤脑转移患者与 ipilimumab-nivolumab 治疗相关的反应和存活率。